RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cannabinoid receptor-interacting
protein 1a modulates CB1 receptor signaling and regulation
Smith, T. H., Blume, L. C., Straiker, A., Cox, J. O., David, B. G., Mcvoy, J. R. S., Sayers, K. W., Poklis, J. L., Abdullah, R. A., Egertova, M., Chen, C.-K., Mackie, K., Elphick, M. R., Howlett, A. C., & Selley, D. E. (2015). Cannabinoid receptor-interacting
protein 1a modulates CB1 receptor signaling and regulation. Molecular Pharmacology, 87(4), 747-765. https://doi.org/10.1124/mol.114.096495
Cannabinoid CB1 receptors (CB(1)Rs) mediate the presynaptic effects of endocannabinoids in the central nervous system (CNS) and most behavioral effects of exogenous cannabinoids. Cannabinoid receptor-interacting protein 1a (CRIP1a) binds to the CB1R C-terminus and can attenuate constitutive CB1R-mediated inhibition of Ca2+ channel activity. We now demonstrate cellular colocalization of CRIP1a at neuronal elements in the CNS and show that CRIP1a inhibits both constitutive and agonist-stimulated CB1R-mediated guanine nucleotide-binding regulatory protein (G-protein) activity. Stable overexpression of CRIP1a in human embryonic kidney (HEK)-293 cells stably expressing CB(1)Rs (CB1-HEK), or in N18TG2 cells endogenously expressing CB(1)Rs, decreased CB1R-mediated G-protein activation (measured by agonist-stimulated [S-35] GTP gamma S (guanylyl-5 '-[O-thio]-triphosphate) binding) in both cell lines and attenuated inverse agonism by rimonabant in CB1-HEK cells. Conversely, small-interfering RNA-mediated knockdown of CRIP1a in N18TG2 cells enhanced CB1R-mediated G-protein activation. These effects were not attributable to differences in CB1R expression or endocannabinoid tone because CB1R levels did not differ between cell lines varying in CRIP1a expression, and endocannabinoid levels were undetectable (CB1-HEK) or unchanged (N18TG2) by CRIP1a overexpression. In CB1-HEK cells, 4-hour pretreatment with cannabinoid agonists downregulated CB(1)Rs and desensitized agonist-stimulated [S-35] GTP gamma S binding. CRIP1a overexpression attenuated CB1R downregulation without altering CB1R desensitization. Finally, in cultured autaptic hippocampal neurons, CRIP1a overexpression attenuated both depolarization-induced suppression of excitation and inhibition of excitatory synaptic activity induced by exogenous application of cannabinoid but not by adenosine A1 agonists. These results confirm that CRIP1a inhibits constitutive CB1R activity and demonstrate that CRIP1a can also inhibit agonist-stimulated CB1R signaling and downregulation of CB(1)Rs. Thus, CRIP1a appears to act as a broad negative regulator of CB1R function.
